Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025

Core Viewpoint - Vivoryon Therapeutics N.V. is set to report its Q1 2025 financial results and operational progress on June 17, 2025, focusing on its development of small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [1][3]. Group 1: Financial Results Announcement - The company will publish its first quarter financial results for the period ended March 31, 2025, on June 17, 2025 [1]. - A corporate update will accompany the financial results announcement [1]. Group 2: Conference Call Details - A conference call will be held on June 17, 2025, at 3:00 pm CEST / 9:00 am EDT, available via phone and webcast [2]. - Participants are encouraged to pre-register for the call to receive dedicated dial-in details and should join 15 minutes early to avoid delays [2]. Group 3: Company Overview - Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for treating inflammatory and fibrotic disorders of the kidney [3]. - The company's leading program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor being evaluated for diabetic kidney disease [3].